Brokerages Set SAB Biotherapeutics, Inc. (NASDAQ:SABS) Price Target at $9.33

SAB Biotherapeutics, Inc. (NASDAQ:SABS) has earned an average recommendation of “Moderate Buy” from the five research firms that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $9.3333.

SABS has been the topic of several recent analyst reports. Leerink Partners initiated coverage on SAB Biotherapeutics in a research note on Wednesday, September 17th. They set an “outperform” rating and a $7.00 target price on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $12.00 price objective on shares of SAB Biotherapeutics in a report on Monday, November 17th. Wall Street Zen upgraded shares of SAB Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 22nd. Leerink Partnrs upgraded shares of SAB Biotherapeutics to a “strong-buy” rating in a research report on Wednesday, September 17th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of SAB Biotherapeutics in a research note on Monday.

SAB Biotherapeutics Trading Down 1.3%

SAB Biotherapeutics stock opened at $3.71 on Thursday. SAB Biotherapeutics has a 52-week low of $1.00 and a 52-week high of $6.60. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $176.63 million, a price-to-earnings ratio of -1.20 and a beta of 0.58. The firm has a 50-day moving average price of $3.18 and a two-hundred day moving average price of $2.49.

SAB Biotherapeutics (NASDAQ:SABS) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.38. Sell-side analysts expect that SAB Biotherapeutics will post -3.69 earnings per share for the current year.

Hedge Funds Weigh In On SAB Biotherapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SABS. Vivo Capital LLC bought a new stake in shares of SAB Biotherapeutics in the 3rd quarter worth $22,954,000. Commodore Capital LP acquired a new position in SAB Biotherapeutics during the third quarter worth about $8,847,000. RA Capital Management L.P. bought a new stake in SAB Biotherapeutics in the third quarter worth about $8,847,000. Woodline Partners LP acquired a new stake in SAB Biotherapeutics in the 3rd quarter valued at about $5,730,000. Finally, HB Wealth Management LLC bought a new position in shares of SAB Biotherapeutics during the 3rd quarter valued at about $618,000. 7.82% of the stock is owned by institutional investors.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.